• linkedin
  • Increase Font
  • Sharebar

    Is focal therapy the future of treatment for localized PCa?


    “People have been looking into focal therapy for a long time now. If you look at the old studies and radical prostatectomy specimens, 85% of prostate cancers are multifocal. That’s why treatment is always the treatment of the total gland, not just the focal area. It even happens with a multiparametric MRI. The MRI may miss a spot. A biopsy can test positive even though nothing was seen on the MRI. So, you run the danger of under-treating patients with focal therapy. That’s been my training and my experience in practice.

    Read: What is the biggest stressor in your office?

    Studies comparing conventional biopsies detected high incidence of high-grade cancer, but actually detected fewer cancers than the biopsies. We don’t have the technology to visualize all the cancers yet, otherwise that should not have happened. The multiparametric MRIs should have had a higher incidence of detection of cancer. There seems to be a potential for higher recurrence by using focal therapies. So the jury is still out.

    I don’t think replacing active surveillance with focal therapy is a real option. When patients choose focal therapy, I think their expectation is to be cured.”

    Young Kang, MD

    Pleasanton, CA

    More from Urology Times:

    How do you approach giving bad news to patients?

    How will the ProtecT study affect your care of PCa patients?

    What is driving younger men to seek treatment for ED?

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.

    Karen Nash
    Karen Nash is a freelance writer based in Sioux Falls, South Dakota.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available